These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 350470)

  • 1. Clinical pharmacokinetics of lignocaine.
    Benowitz NL; Meister W
    Clin Pharmacokinet; 1978; 3(3):177-201. PubMed ID: 350470
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The pharmacokinetics of lignocaine and beta-adrenoceptor antagonists in patients with acute myocardial infarction.
    Nattel S; Gagne G; Pineau M
    Clin Pharmacokinet; 1987 Nov; 13(5):293-316. PubMed ID: 2891461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics in patients with cardiac failure.
    Benowitz NL; Meister W
    Clin Pharmacokinet; 1976; 1(6):389-405. PubMed ID: 799548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tocainide. A review of its pharmacological properties and therapeutic efficacy.
    Holmes B; Brogden RN; Heel RC; Speight TM; Avery GS
    Drugs; 1983 Aug; 26(2):93-123. PubMed ID: 6411445
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical pharmacokinetics of the newer antiarrhythmic agents.
    Gillis AM; Kates RE
    Clin Pharmacokinet; 1984; 9(5):375-403. PubMed ID: 6437721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lignocaine and indocyanine green kinetics in patients following myocardial infarction.
    Bax ND; Tucker GT; Woods HF
    Br J Clin Pharmacol; 1980 Oct; 10(4):353-61. PubMed ID: 7448106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic principles of lidocaine dosing in relation to disease state.
    Waller ES
    J Clin Pharmacol; 1981 Apr; 21(4):181-94. PubMed ID: 7240439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lignocaine prophylaxis in acute myocardial infarction: an evaluation of randomised trials.
    DeSilva RA; Hennekens CH; Lown B; Casscells W
    Lancet; 1981 Oct; 2(8251):855-8. PubMed ID: 6116964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors affecting free (unbound) lignocaine concentration in suspected acute myocardial infarction.
    Routledge PA; Stargel WW; Barchowsky A; Wagner GS; Shand DG
    Br J Clin Pharmacol; 1989 Nov; 28(5):593-7. PubMed ID: 2590613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impaired Lignocaine metabolism in patients with myocardial infarction and cardiac failure.
    Prescott LF; Adjepon-Yamoah KK; Talbot RG
    Br Med J; 1976 Apr; 1(6015):939-41. PubMed ID: 1268491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. On the role of alpha 1-acid glycoprotein in lignocaine accumulation following myocardial infarction.
    Barchowsky A; Shand DG; Stargel WW; Wagner GS; Routledge PA
    Br J Clin Pharmacol; 1982 Mar; 13(3):411-5. PubMed ID: 7059443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tolerability and antiarrhythmic efficacy of disopyramide compared to lignocaine in selected patients with suspected acute myocardial infarction.
    Rønnevik PK; Gundersen T; Abrahamsen AM
    Eur Heart J; 1987 Jan; 8(1):19-24. PubMed ID: 2880718
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in lignocaine disposition during long-term infusion in patients with acute ventricular arrhythmias.
    Thomson AH; Kelman AW; de Vane PJ; Hillis WS; Whiting B
    Ther Drug Monit; 1987 Sep; 9(3):283-91. PubMed ID: 3672571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lignocaine therapy after acute myocardial infarction.
    Chopra MP; Portal RW; Aber CP
    Br Med J; 1969 Jan; 1(5638):213-6. PubMed ID: 5762622
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiarrhythmic action of lignocaine in early myocardial infarction. Plasma levels after combined intramuscular and intravenous administration.
    Sheridan DJ; Crawford L; Rawlins MD; Julian DG
    Lancet; 1977 Apr; 1(8016):824-5. PubMed ID: 67335
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mexiletine: a review of its pharmacological properties and therapeutic efficacy in arrhythmias.
    Chew CY; Collett J; Singh BN
    Drugs; 1979 Mar; 17(3):161-81. PubMed ID: 378646
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lignocaine kinetics in cardiac patients and aged subjects.
    Nation RL; Triggs EJ; Selig M
    Br J Clin Pharmacol; 1977 Aug; 4(4):439-48. PubMed ID: 901735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic and pharmacodynamic considerations in drug therapy of cardiac emergencies.
    Pentel P; Benowitz N
    Clin Pharmacokinet; 1984; 9(4):273-308. PubMed ID: 6380870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of lignocaine on plasma protein binding and pharmacokinetics of verapamil in dogs.
    Belpaire FM; De Rick A; Bourda A; De Smet F; Rosseel MT; Bogaert MG
    J Pharm Pharmacol; 1990 Jan; 42(1):45-9. PubMed ID: 1969949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Age-dependent lidocaine disposition in patients with acute myocardial infarction.
    Cusson J; Nattel S; Matthews C; Talajic M; Lawand S
    Clin Pharmacol Ther; 1985 Apr; 37(4):381-6. PubMed ID: 3978999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.